Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers

Inclusion Criteria: * Male gender * Age ≥35 * Current smoker of at least 10 cigarettes per day with history of ≥10 pack-years (py) * Former smoker, quit no more than 15 years ago with a history of at least 25 py * Ability to comply with the design of the study * Capacity to freeze urine sample at participant's residence if this participant desires to store the urine specimens in this manner * Baseline urine PGE-M \> 13 ng/mg creatinine * Serum thromboxane \> 150 μg/L Exclusion Criteria: * History of aspirin use 1-14 days prior to screening * NSAID (ibuprofen, naprosyn, meloxicam, etc) use 1-7 days prior to screening * Inhaled glucocorticoid use 1-7 days prior to screening * Systemic glucocorticoid use 1-14 days prior to screening * History of peptic ulcer disease * Current or recent clinically significant bleeding * Allergy, intolerance or contraindication to aspirin or NSAID use * Thrombocytopenia (platelet count \< 100,000) in 30 days prior to screening visit * Severe hepatic insufficiency * GFR \< 30 mL/min/1.73 m2 in 30 days prior to screening visit * History of aspirin or celecoxib allergy * Elevated INR (\>1.5) in 30 days prior to screening visit * Current diagnosis of malignancy or history of non-skin malignancy in last 5 years * Current use of systemic anticoagulants (e.g., warfarin (Coumadin), enoxaparin (Lovenox), Fondaparinux (Arixtra), dabigatran (Pradaxa)) * Diagnosis of COPD * Intake of \> 250 mg of fish oil supplementation daily